down arrow

Moleculin Biotech, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US60855D2009
USD
3.90
-0.11 (-2.74%)

Dec 24

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

3.784.18

52 Week

3.6391.25
Valuation
Technical
Day's Volume

CASH

126.03 k

Shareholding (Mar 2025)

FII

0.11%

Held by 4 FIIs

DII

99.24%

Held by 1 DIIs

Promoter

0.00%

How big is Moleculin Biotech, Inc.?

22-Jun-2025

As of Jun 18, Moleculin Biotech, Inc. has a market capitalization of 9.41 million and reported net sales of 0.00 million with a net profit of -23.23 million over the last four quarters. The balance sheet shows shareholder's funds of 5.98 million and total assets of 16.93 million.

As of Jun 18, Moleculin Biotech, Inc. has a market capitalization of 9.41 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters, with a net profit of -23.23 million during the same period.<BR><BR>As of Dec 24, the balance sheet shows shareholder's funds of 5.98 million and total assets of 16.93 million.

Read More

What does Moleculin Biotech, Inc. do?

22-Jun-2025

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company focused on cancer treatments, with a market cap of $9.41 million and a recent net profit of -$6 million. The company operates in the Pharmaceuticals & Biotechnology industry and has no dividend yield or positive earnings.

Overview: <BR>Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company focused on the treatment of cancers, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -6 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 9.41 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -7.59 <BR>Return on Equity: -3,695.30% <BR>Price to Book: 9.41<BR><BR>Contact Details: <BR>Address: 5300 Memorial Dr Ste 950, HOUSTON TX: 77007-8274 <BR>Tel: 1 713 3005160 <BR>Website: http://www.moleculin.com/

Read More

Is Moleculin Biotech, Inc. technically bullish or bearish?

20-Sep-2025

As of August 14, 2025, Moleculin Biotech, Inc. has shifted to a mildly bearish trend, with daily moving averages indicating bearish momentum and a year-to-date return of -75.76%, significantly underperforming the S&P 500's 12.22%.

As of 14 August 2025, the technical trend for Moleculin Biotech, Inc. has changed from sideways to mildly bearish. The current stance is bearish, driven primarily by the daily moving averages indicating bearish momentum. While the weekly MACD and KST show mildly bullish signals, the overall indicators, including Bollinger Bands and the daily moving averages, suggest weakness in the trend. The stock has significantly underperformed against the S&P 500, with a year-to-date return of -75.76% compared to the benchmark's 12.22%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 12 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

1.04

stock-summary
Return on Equity

672.53%

stock-summary
Price to Book

-1.64

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-8 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-63.7%
0%
-63.7%
6 Months
-43.04%
0%
-43.04%
1 Year
-90.98%
0%
-90.98%
2 Years
-98.47%
0%
-98.47%
3 Years
-99.14%
0%
-99.14%
4 Years
-99.49%
0%
-99.49%
5 Years
-99.78%
0%
-99.78%

Moleculin Biotech, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-7.15%
EBIT to Interest (avg)
-24.60
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-7.59
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
12.88%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
9.47
EV to EBIT
-0.07
EV to EBITDA
-0.07
EV to Capital Employed
-0.25
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-3695.30%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 3 Schemes (0.65%)

Foreign Institutions

Held by 4 Foreign Institutions (0.11%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -76.74% vs 28.33% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.70",
          "val2": "-6.20",
          "chgp": "8.06%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "9.60",
          "val2": "1.70",
          "chgp": "464.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-7.60",
          "val2": "-4.30",
          "chgp": "-76.74%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 26.85% vs -2.76% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-26.50",
          "val2": "-29.50",
          "chgp": "10.17%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "4.30",
          "val2": "-1.00",
          "chgp": "530.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-21.80",
          "val2": "-29.80",
          "chgp": "26.85%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-5.70
-6.20
8.06%
Interest
0.00
0.00
Exceptional Items
9.60
1.70
464.71%
Consolidate Net Profit
-7.60
-4.30
-76.74%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -76.74% vs 28.33% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-26.50
-29.50
10.17%
Interest
0.00
0.00
Exceptional Items
4.30
-1.00
530.00%
Consolidate Net Profit
-21.80
-29.80
26.85%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 26.85% vs -2.76% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Moleculin Biotech, Inc. stock-summary
stock-summary
Moleculin Biotech, Inc.
Pharmaceuticals & Biotechnology
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the treatment of cancers. Its clinical stage drug candidates include Annamycin, WP1066, WP1220, WP1732, WP1122 and WP1234. Annamycin is intended for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. WP1066 is an immune/transcription modulator (p-STAT3 inhibitor) and is intended to target a wide range of tumors, including brain tumors and pancreatic cancer. WP1220 is intended for the topical treatment of cutaneous T-cell lymphoma (CTCL). WP1732 is evaluated for the potential treatment of AML, pancreatic and other cancers. WP1122 and WP1234 are evaluated for the potential to treat brain tumors and pancreatic cancer through its ability to inhibit glycolysis. It is also engaged in development of drug candidates, including additional immune/transcription modulators, as well as metabolism/glycosylation inhibitors.
Company Coordinates stock-summary
Company Details
5300 Memorial Dr Ste 950 , HOUSTON TX : 77007-8274
stock-summary
Tel: 1 713 3005160
stock-summary
http://www.moleculin.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."